GlassScriptPhysician profile
Robert Lane Topkis
NPI 1649367681
$28,334.88
in general payments reported to CMS, 2019-2025
62 companies · $3,676 in 2025
The $3,676 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,112 · 2020: $3,621 · 2021: $4,097 · 2022: $2,915 · 2023: $3,887 · 2024: $5,027 · 2025: $3,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,299.56 |
| Education | $289.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,014.65 | 2019-2025 | |
| Abbvie INC. | $2,725.45 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $2,684.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,806.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,585.47 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $1,583.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,420.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $1,035.59 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $979.78 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $794.91 | 2019-2025 | |
| Abbott Laboratories | $777.67 | 2021-2025 | Freestyle Libre 3, Proclaim, Swift-Lock |
| Amgen INC. | $773.52 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $750.24 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $596.88 | 2022-2025 | Caplyta |
| Allergan, INC. | $592.49 | 2019-2021 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Topkis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.